#24. The Surprising Risks of Marketing CBD Products – with Asa Waldstein (podcast)
Podcast Show Notes with Asa Waldstein
In this engaging conversation with FDA compliance expert Asa Waldstein, we discuss how to avoid a FDA warning letter which surprisingly goes way beyond what businesses state on a product label. We cover best practices for CBD company social media managers, effective marketing messages with lower risk language, dos and don’ts of reposting and hashtags, mitigating compliance risk, avoiding making CBD health claims and how to market your products instead.
You will find out what it means for Asa to Create Authentic Excitement in your differentiation strategy and the peace of mind you may get from it.
We also discuss cGMP compliance and Asa’s recommendations for Spectrum Labs’ GMP accreditation journey.
You may connect with Asa on his LinkedIn and website. Read more about the Warning Letter Review blog post referenced in this episode.